Catalent, Inc.CTLT

時価総額

$115.2億

PER

医薬品・バイオ、細胞・遺伝子治療の開発・製造の最大手。ソフトゲルやZydis、GPEx、AAV、pDNAなどの先端プラットフォームを展開。2024年2月にNovo Holdingsによる165億ドルでの買収合意。世界4大陸約50拠点で展開。

概要財務

サマリーテーブルに戻る

	2014年 6月30日	2015年 6月30日	2016年 6月30日	2017年 6月30日	2018年 6月30日	2019年 6月30日	2020年 6月30日	2021年 6月30日	2022年 6月30日	2023年 6月30日	2024年 6月30日
Proceeds from Sale and Maturity of Marketable Securities	-	-	-	-	-	-	-	-	-	89	-
Payments to Acquire Debt Securities, Available-for-sale	-	-	-	-	-	-	-	72	20	-	-
Proceeds from sale of property and equipment	1	-	2	1	2	1	-	-	-	8	1
Settlement on from sale of subsidiaries	-	-	-	-	-	-	-	-	-3	-	-
Proceeds from Divestiture of Interest in Consolidated Subsidiaries	-	-	-	-	3	-	21	287	-	-	-
Payment for acquisitions, net of cash acquired	54	131	-	170	748	1,291	380	147	1,199	474	-
Payments to Acquire Investments	-	-	-	-	-	-	-	31	2	2	1
Segment, Expenditure, Addition to Long-Lived Assets	122	141	-	-	-	-	-	-	-	576	327
Net cash (used in) investing activities	-171	-272	-138	-309	-919	-1,510	-827	-649	-1,884	-955	-327
Net change in other borrowings	-17	-	2	-6	-3	-8	-49	2	-	-	-
Proceeds from borrowing, net	-	-	-	-	443	1,448	909	164	1,100	715	1,200
Repayments of Long-term Debt	1,741	880	19	219	19	1,290	811	67	78	230	1,116
Payments of Debt Issuance Costs	-	-	-	6	16	25	25	19	15	4	16
Proceeds from Issuance of Common Stock	-	-	-	-	-	446	1,047	82	-	-	-
Proceeds from Stock Options Exercised	-	-	-	-	-	-	-	38	26	4	9
Payments Related to Tax Withholding for Share-based Compensation	-	-	9	5	14	15	32	46	10	-	-
Proceeds from (Payments for) Other Financing Activities	-	-	-	-	-	-	-	10	12	36	-3
Net cash provided by/(used in) financing activities	-42	197	-31	161	669	1,201	1,002	142	1,031	521	74
Net earnings	15	210	111	110	84	137	221	585	519	-256	-1,043
Depreciation and Amortization	143	141	141	147	190	229	254	289	378	422	489
Goodwill, Impairment Loss	-	-	-	-	-	-	-	-	-	210	687
Foreign Currency Transaction Gain (Loss), before Tax	17	16	11	-8	3	1	-2	4	-30	9	-13
Amortization And Write Off Of Financing Costs	14	16	5	7	5	14	12	11	7	8	14
Gain (Loss) on Sale of Assets and Asset Impairment Charges	-	-	-3	-10	-9	-5	-5	-9	-31	-98	-29
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	-	-	-	-	-	-	-	182	1	-	-
Financing fees paid	-	-	-	-	12	5	10	18	4	-	-
Derivative, Gain (Loss) on Derivative, Net	-	-	-	-	-	13	3	17	2	-	-
Equity compensation	5	9	11	21	27	33	48	51	54	35	68
Provision/(benefit) for deferred income taxes	15	121	15	1	-35	15	-2	-64	-14	127	28
Provision for bad debts and inventory	10	13	13	11	7	13	10	41	17	143	82
(Increase)/decrease in trade receivables	38	8	54	55	34	119	151	186	73	-53	-79
(Increase)/decrease in inventories	9	19	35	14	2	34	76	260	128	192	-109
Increase/(decrease) in accounts payable	-8	-12	21	10	32	36	72	50	37	-21	-84
Other assets/accrued liabilities, net - current and non-current	-67	50	34	-47	-12	44	-34	36	448	128	166
Net Cash Provided by (Used in) Operating Activities, Total	178	172	155	300	375	248	440	433	439	254	268
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	-	-	-	-	-	-	-	-	-33	11	-6
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	-	-	-	-	-	-	608	-57	-447	-169	9
Stock Issued During Period, Value, Conversion of Convertible Securities	-	-	-	-	-	-	-	253	362	-	-
Interest paid	154	107	82	81	83	103	98	105	116	188	226
Income taxes paid, net	21	34	41	40	24	42	43	47	53	99	43
Capital Expenditures Incurred but Not yet Paid	-	-	-	-	-	-	-	-	-	18	24
Restructuring Reserve, Settled without Cash	-	-	-	-	-	-	-	-	-	18	7
Debtor Reorganization Items, Pension and Other Postretirement Related Charges	-	-	-	-	-	-	-	-	-	-	12
Other Operating Activities, Cash Flow Statement	-	-	-	-	-	-	-	-	-	-	1